Article Text

Download PDFPDF
Systematic review
Lung cancer screening with low-dose CT: benefits and potential risks
  1. Nichole T Tanner,
  2. Gerard A Silvestri
  1. Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, 96 Jonathan Lucas Street, CSB Suite 812, Charleston, SC 29425, USA
  1. Correspondence to : Dr Nichole T Tanner
    Medical Univestity of South Carolina, Charleston, SC 29425, USA; tripici{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrl


Lung cancer is the leading cause of cancer death worldwide.1 The majority of patients present with advanced disease and the current 5-year survival is only 15%.2 Previous research showed no mortality benefit to screening with chest radiography and sputum cytology. The recent results of the National Lung Screening Trial (NLST) are the first to show a significant reduction in lung cancer mortality with the use of low-dose CT (LDCT) in high risk individuals. The potential for harm with screening and generalisability of results have been a cause for concern in initiation of lung cancer screening programmes. As such, a multisociety collaborative initiative was undertaken to develop the foundation for a clinical guideline for lung cancer screening.


The authors performed a literature search using MEDLINE, EMBASE and the Cochrane Library databases …

View Full Text


  • Competing interests None.